REFERENCES
1. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW,
Zhuang Z, Lubensky I, Dean M, Allikmets R, Chidambaram A, Bergerheim UR,
Feltis JT, Casadevall C, Zamarron A, Bernues M, Richard S, Lips CJ,
Walther MM, Tsui LC, Geil L, Orcutt ML, Stackhouse T, Lipan J, Slife L,
Brauch H, Decker J, Niehans G, Hughson MD, Moch H, Storkel S, Lerman MI,
Linehan WM, Zbar B. Germline And Somatic Mutations In The Tyrosine
Kinase Domain Of The MET Proto-Oncogene In Papillary Renal Carcinomas.
Nature Genetics 1997; 16: 68-73.
2. Di Renzo MF, Olivero M, Martone T, Maffe A, Maggiora P, Stefani AD,
Valente G, Giordano S, Cortesina G, Comoglio PM. Somatic Mutations Of
The MET Oncogene Are Selected During Metastatic Spread Of Human HNSC
Carcinomas. Oncogene 2000; 19: 1547-55.
3. Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, Chen
J, Wang X, Ruslim L, Blake R, Lipson KE, Ramphal J, Do S, Cui JJ,
Cherrington JM, Mendel DB. A Selective Small Molecule Inhibitor Of C-Met
Kinase Inhibits C-Met-Dependent Phenotypes In Vitro And Exhibits
Cytoreductive Antitumor Activity In Vivo. Cancer Research 2003; 63:
7345-55.
4. Davis IJ, Mcfadden AW, Zhang Y, Coxon A, Burgess TL, Wagner AJ,
Fisher DE. Identification Of The Receptor Tyrosine Kinase C-Met And Its
Ligand, Hepatocyte Growth Factor, As Therapeutic Targets In Clear Cell
Sarcoma. Cancer Research 2010; 70: 639-45.
5. Akervall J, Guo X, Qian CN, Schoumans J, Leeser B, Kort E, Cole A,
Resau J, Bradford C, Carey T, Wennerberg J, Anderson H, Tennvall J, Teh
BT. Genetic And Expression Profiles Of Squamous Cell Carcinoma Of The
Head And Neck Correlate With Cisplatin Sensitivity And Resistance In
Cell Lines And Patients. Clinical Cancer Research : An Official Journal
Of The American Association For Cancer Research 2004; 10: 8204-13.
6. Lal B, Xia S, Abounader R, Laterra J. Targeting The C-Met Pathway
Potentiates Glioblastoma Responses To Gamma-Radiation. Clinical Cancer
Research : An Official Journal Of The American Association For Cancer
Research 2005; 11: 4479-86.
7. Liu X, Yao W, Newton RC, Scherle PA. Targeting The C-MET Signaling
Pathway For Cancer Therapy. Expert Opinion On Investigational Drugs
2008; 17: 997-1011.
8. Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, Felicioni L,
Del Grammastro M, Sciarrotta MG, Buttitta F, Incarbone M, Toschi L,
Finocchiaro G, Destro A, Terracciano L, Roncalli M, Alloisio M, Santoro
A, Varella-Garcia M. Increased MET Gene Copy Number Negatively Affects
Survival Of Surgically Resected Non-Small-Cell Lung Cancer Patients.
Journal Of Clinical Oncology : Official Journal Of The American Society
Of Clinical Oncology 2009; 27: 1667-74.
9. Sierra JR, Tsao MS. C-MET As A Potential Therapeutic Target And
Biomarker In Cancer. Therapeutic Advances In Medical Oncology 2011; 3:
S21-35.
10. US Food And Drug Administration. Capmatinib Oral Tablet Prescribing
Information. Available At:
Https://Www.Accessdata.Fda.Gov/Drugsatfda_Docs/Label/2020/213591s000lbl.Pdf.
Accessed On 18 May 2020.
11. Liu X, Wang Q, Yang G, Marando C, Koblish HK, Hall LM, Fridman JS,
Behshad E, Wynn R, Li Y, Boer J, Diamond S, He C, Xu M, Zhuo J, Yao W,
Newton RC, Scherle PA. A Novel Kinase Inhibitor, INCB28060, Blocks
C-MET-Dependent Signaling, Neoplastic Activities, And Cross-Talk With
EGFR And HER-3. Clinical Cancer Research : An Official Journal Of The
American Association For Cancer Research 2011; 17: 7127-38.
12. Baltschukat S, Engstler BS, Huang A, Hao HX, Tam A, Wang HQ, Liang
J, Dimare MT, Bhang HC, Wang Y, Furet P, Sellers WR, Hofmann F,
Schoepfer J, Tiedt R. Capmatinib (INC280) Is Active Against Models Of
Non-Small Cell Lung Cancer And Other Cancer Types With Defined
Mechanisms Of MET Activation. Clinical Cancer Research : An Official
Journal Of The American Association For Cancer Research 2019; 25:
3164-75.
13. Schuler MH, Berardi R, Lim W-T, Geel RV, Jonge MJD, Bauer TM, Azaro
A, Gottfried M, Han J-Y, Lee DH, Wollner M, Hong DS, Vogel A, Delmonte
A, Krohn A, Zhang Y, Squires M, Giovannini M, Akimov M, Bang Y-J. Phase
(Ph) I Study Of The Safety And Efficacy Of The Cmet Inhibitor Capmatinib
(INC280) In Patients (Pts) With Advanced Cmet+ Non-Small Cell Lung
Cancer (NSCLC). Journal Of Clinical Oncology 2016; 34: 9067-67.
14. Wu YL, Zhang L, Kim DW, Liu X, Lee DH, Yang JC, Ahn MJ,
Vansteenkiste JF, Su WC, Felip E, Chia V, Glaser S, Pultar P, Zhao S,
Peng B, Akimov M, Tan DSW. Phase Ib/II Study Of Capmatinib (INC280) Plus
Gefitinib After Failure Of Epidermal Growth Factor Receptor (EGFR)
Inhibitor Therapy In Patients With EGFR-Mutated, MET Factor-Dysregulated
Non-Small-Cell Lung Cancer. Journal Of Clinical Oncology : Official
Journal Of The American Society Of Clinical Oncology 2018; 36: 3101-09.
15. Wolf J, Han J, Nishio M, Souquet P, Paz-Ares L, De Marinis F, Seto
T, De Jonge M, Kim TM, Vansteenkiste J, Tan Dsw, Garon EB, Groen H,
Hochmair MJ, Felip E, Reguart N, Thomas M, Overbeck T, Ohashi K,
Giovannini M, Yura R, Joshi A, Akimov M, Heist R. PS04.06 GEOMETRY
Mono-1: Phase II, Multicenter Study Of MET Inhibitor Capmatinib (INC280)
In EGFR Wt, MET-Dysregulated Advanced NSCLC. Journal Of Thoracic
Oncology 2017; 12: S1578-S79.
16. Bang Y-J, Su W-C, Nam D-H, Lim W-T, Bauer TM, Brana I, Poon RT-P,
Hong DS, Lin C-C, Peng B, Zhang Y, Zhao S, Kumar A, Akimov M, Ma B.
Phase I Study Of The Safety And Efficacy Of INC280 In Patients With
Advanced MET-Dependent Solid Tumors. Journal Of Clinical Oncology 2014;
32: 2520-20.
17. Esaki T, Hirai F, Makiyama A, Seto T, Bando H, Naito Y, Yoh K,
Ishihara K, Kakizume T, Natsume K, Myers A, Doi T. Phase I
Dose-Escalation Study Of Capmatinib (INC280) In Japanese Patients With
Advanced Solid Tumors. Cancer Science 2019; 110: 1340-51.
18. Bang YJ, Su WC, Schuler M, Nam DH, Lim WT, Bauer TM, Azaro A, Poon
RTP, Hong D, Lin CC, Akimov M, Ghebremariam S, Zhao S, Giovannini M, Ma
B. Phase 1 Study Of Capmatinib In MET-Positive Solid Tumor Patients:
Dose Escalation And Expansion Of Selected Cohorts. Cancer Science 2020;
111: 536-47.
19. Qin S, Chan SL, Sukeepaisarnjaroen W, Han G, Choo SP, Sriuranpong V,
Pan H, Yau T, Guo Y, Chen M, Ren Z, Xu J, Yen CJ, Lin ZZ, Manenti L, Gu
Y, Sun Y, Tiedt R, Hao L, Song W, Tanwandee T. A Phase II Study Of The
Efficacy And Safety Of The MET Inhibitor Capmatinib (INC280) In Patients
With Advanced Hepatocellular Carcinoma. Therapeutic Advances In Medical
Oncology 2019; 11: 1758835919889001.
20. Reungwetwattana T, Liang Y, Zhu V, Ou SI. The Race To Target MET
Exon 14 Skipping Alterations In Non-Small Cell Lung Cancer: The Why, The
How, The Who, The Unknown, And The Inevitable. Lung Cancer (Amsterdam,
Netherlands) 2017; 103: 27-37.
21. Feliu J, Heredia-Soto V, Girones R, Jimenez-Munarriz B, Saldana J,
Guillen-Ponce C, Molina-Garrido MJ. Can We Avoid The Toxicity Of
Chemotherapy In Elderly Cancer Patients? Critical Reviews In
Oncology/Hematology 2018; 131: 16-23.
22. Van Leeuwen RW, Van Gelder T, Mathijssen RH, Jansman FG. Drug-Drug
Interactions With Tyrosine-Kinase Inhibitors: A Clinical Perspective.
The Lancet Oncology 2014; 15: E315-26.
23. Turpault S, Brian W, Van Horn R, Santoni A, Poitiers F, Donazzolo Y,
Boulenc X. Pharmacokinetic Assessment Of A Five-Probe Cocktail For Cyps
1A2, 2C9, 2C19, 2D6 And 3A. British Journal Of Clinical Pharmacology
2009; 68: 928-35.
24. Otani N, Wakuda H, Imai H, Kuranari M, Ishii Y, Ito Y, Okubo A,
Ogawa O, Takeda K, Ohyama T, Hasunuma T, Uemura N. No Effect Of Digoxin
On Rosuvastatin Pharmacokinetics In Healthy Subjects: Utility Of Oita
Combination For Clinical Drug-Drug Interaction Study. Clinical And
Translational Science 2019.
25. Einfeld SL, Piccinin AM, Mackinnon A, Hofer SM, Taffe J, Gray KM,
Bontempo DE, Hoffman LR, Parmenter T, Tonge BJ. Psychopathology In Young
People With Intellectual Disability. Jama 2006; 296: 1981-9.
26. Tye C, Mcewen FS, Liang H, Underwood L, Woodhouse E, Barker ED,
Sheerin F, Yates JRW, Bolton PF. Long-Term Cognitive Outcomes In
Tuberous Sclerosis Complex. Developmental Medicine And Child Neurology
2020; 62: 322-29.
27. Krueger DA, Northrup H. Tuberous Sclerosis Complex Surveillance And
Management: Recommendations Of The 2012 International Tuberous Sclerosis
Complex Consensus Conference. Pediatric Neurology 2013; 49: 255-65.
28. Nabbout R, Belousova E, Benedik MP, Carter T, Cottin V, Curatolo P,
Dahlin M, L DA, d’Augeres GB, De Vries PJ, Ferreira JC, Feucht M,
Fladrowski C, Hertzberg C, Jozwiak S, Lawson JA, Macaya A, Marques R,
O’Callaghan F, Qin J, Sander V, Sauter M, Shah S, Takahashi Y, Touraine
R, Youroukos S, Zonnenberg B, Jansen A, Kingswood JC. Epilepsy In
Tuberous Sclerosis Complex: Findings From The TOSCA Study. Epilepsia
Open 2019; 4: 73-84.
29. Martin PD, Kemp J, Dane AL, Warwick MJ, Schneck DW. No Effect Of
Rosuvastatin On The Pharmacokinetics Of Digoxin In Healthy Volunteers.
Journal Of Clinical Pharmacology 2002; 42: 1352-7.
30. Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, Moore
R, Lee C, Chen Y, Schneck D. Rosuvastatin Pharmacokinetics And
Pharmacogenetics In White And Asian Subjects Residing In The Same
Environment. Clinical Pharmacology And Therapeutics 2005; 78: 330-41.
31. US Food And Drug Administration. In Vitro Metabolism‐ And
Transporter‐Mediated Drug‐Drug Interaction Studies: Guidance For
Industry. [Draft Guidance 2017]. Available At:
Https://Www.Fda.Gov/Regulatory-Information/Search-Fda-Guidance-Documents/Vitro-Metabolism-And-Transporter-Mediated-Drug-Drug-Interaction-Studies-Guidance-Industry.
Accessed On 18 May 2020.